92 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
and overseeing the company’s overall compensation strategy and policies in light of our specific business objectives;
reviewing and approving the compensation … strategy and operations. Our board of directors and our nominating and corporate governance committee seek individuals with backgrounds and qualities
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
successfully executing our sales and marketing strategy of KIMMTRAK in the United States, Europe and elsewhere, including continuing to successfully … to continue successfully executing our sales and marketing strategy of KIMMTRAK in the United States, Europe and elsewhere, including continuing
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
, modifying and overseeing the company’s overall compensation strategy and policies in light of our specific business objectives;
reviewing and approving … with respect to our strategy and operations. Our board of directors and our nominating and corporate governance committee seek individuals with backgrounds
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
to continue successfully executing our sales and marketing strategy of KIMMTRAK in the United States, Europe and elsewhere, including continuing … strategy and adversely affect the market price of our ADSs.
You may experience immediate and substantial dilution in the book value per ADS that you
8-K
EX-99.1
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
an offering of convertible notes with a six-year term and 2.50% interest rate (Convertible Notes).
KIMMTRAK expansion strategy
KIMMTRAK® (tebentafusp … , strategy and anticipated milestones, including Immunocore’s ability to conduct ongoing and planned clinical trials; Immunocore’s ability to obtain
8-K
EX-99.2
ey2edro
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
10-K
EX-10.12
g26neu 51
28 Feb 24
Annual report
7:33am
10-K
EX-10.14
itl5g4fgsyx3rhgcl02
28 Feb 24
Annual report
7:33am
10-K
t3niedwhwt474z
28 Feb 24
Annual report
7:33am
8-K
EX-99.2
w0hl25bh1c608i3 2y2a
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
8-K
EX-99.1
d6c6c8r
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
6-K
EX-99.3
ivzq0ky4rtt8jthrif
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.2
c8nuigimtzw75 acv
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.1
26l1wg1xk64n g8822
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
6vpext53b1yafwc 0wxq
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.4
kpaut559rd em8q5j
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
3mu0o2ol4wa2stvxbw3q
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
qe379v4tyce4nwv 4g
10 Aug 23
Current report (foreign)
8:28am
6-K
e2013wq5w
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
EX-99.1
snyf67
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am